Clinical Trial: Juno Therapeutics CAR T Cell Therapy for Relapsed or Refractory Myeloma
Posted: Feb 12, 2018
Clinical Trial: Juno Therapeutics CAR T Cell Therapy for Relapsed or Refractory Myeloma image

Juno Therapeutics today opens its Phase 1/2 study to determine the safety and efficacy of JCARH125, a CAR T-cell product that targets B-cell maturation antigen (BCMA), in adult patients s with relapsed or refractory multiple myeloma. The study will include a Phase 1 part to determine the recommended dose of JCARH125, followed by a Phase 2 part to further evaluate the safety and efficacy of JCARH125 at the recommended dose.

Juno Therapeutics and Celgene have announced a partnership on this CAR T product. The study is open at Memorial Sloan Kettering Cancer Center and is anticipated to be open at additional centers in the future.

Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JCARH125 administered intravenously (IV).

To learn more, click here: Juno CAR T Clinical Trial

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811